Biopharma partnering
Inform & derisk pharmaceutical innovation
Partner with us to access the deepest insights, novel targets and mechanistic biomarker in complex, chronic diseases
Select the right targets
Accelerate & derisk innovation
Increase the probability of R&D success
Take new drugs to market faster
NTDx novel target discovery
Our disease studies help kick start your discovery programs and enhance the mapping of target biology to patient subgroups for compounds already in development.
We generate deep biological insights into targets and mechanisms for your patient population, uncovering patient subgroups with distinct disease etiologies to find new targets for therapeutic intervention.
INDx indication extension
Our systematic analysis identifies patentable opportunities to optimize your pipeline value by licensing assets with applications in secondary indications, supported by stratification biomarkers to identify potential responders.
Annual INDx subscription ensures that you are kept up to date with new opportunities as your pipeline evolves and our disease coverage expands.
CTAx clinical trial analysis
We dissect your clinical trial data, rapidly yielding a deep understanding of response prediction, patient stratification and drug response biomarkers and potential novel targets.
These insights clearly delineate likely responders from non-responders to inform patient selection criteria to design more targeted trials, enriched clinical trials with greater probability of success.
text
text
NTDx novel target discovery
Our disease studies help kick start your discovery programs and enhance the mapping of target biology to patient subgroups for compounds already in development.
We generate deep biological insights into targets and mechanisms for your patient population, uncovering patient subgroups with distinct disease etiologies to find new targets for therapeutic intervention.
INDx indication extension
Our systematic analysis identifies patentable opportunities to optimize your pipeline value by licensing assets with applications in secondary indications, supported by stratification biomarkers to identify potential responders.
Annual INDx subscription ensures that you are kept up to date with new opportunities as your pipeline evolves and our disease coverage expands.
CTAx clinical trial analysis
We dissect your clinical trial data, rapidly yielding a deep understanding of response prediction, patient stratification and drug response biomarkers and potential novel targets.
These insights clearly delineate likely responders from non-responders to inform patient selection criteria to design more targeted trials, enriched clinical trials with greater probability of success.